Evaluation of the Interobserver Agreement in the Number of Mitotic Figures Breast Carcinoma as Simulation of Quality Monitoring in the Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) Protocol-Reference-Cited by-同舟云学术

Evaluation of the Interobserver Agreement in the Number of Mitotic Figures Breast Carcinoma as Simulation of Quality Monitoring in the Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) Protocol

Published:2000-04 Issue:4 Volume:91 Page:451-457
ISSN:0910-5050
Container-title:Japanese Journal of Cancer Research
language:en
Short-container-title:

Author:

Tsuda Hitoshi,Akiyama Futoshi,Kurosumi Masafumi,Sakamoto Goi,Yamashiro Katsushige,Oyama Tetsunari,Hasebe Takahiro,Kameyama Kaori,Hasegawa Tadashi,Umemura Shinobu,Honma Keiichi,Ozawa Takachika,Sasaki Keiko,Morino Hideo,Ohsumi Shozo

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1349-7006.2000.tb00966.x/fullpdf

Reference16 articles.

1. Histological grading and prognosis in breast cancer;Bloom;Br. J. Cancer,1957

2. The importance of histologic grade in long-term prognosis of breast cancer: a study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy;Contesso;J. Clin. Oncol.,1987

3. Expression of mitoses per thousand cells and cell density in breast carcinomas: a proposal;Simpson;Hum. Pathol.,1992

4. Reproducibility of mitosis counting in 2,469 breast-cancer specimens: results from the multicenter morphometric mammary carcinoma project;Diest;Hum. Pathol.,1992

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessment of nuclear grade-based recurrence risk classification in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, node-positive high-risk early breast cancer;Breast Cancer;2023-08-23

2. Improving mitotic cell counting accuracy and efficiency using phosphohistone‐H3 ( PHH3 ) antibody counterstained with haematoxylin and eosin as part of breast cancer grading;Histopathology;2022-11-18

3. The current staging and classification systems of breast cancer and their pitfalls: Is it possible to integrate the complexity of this neoplasm into a unified staging system?;Critical Reviews in Oncology/Hematology;2022-10

4. Validation of a nuclear grading system for resected stage I–IIIA, high-risk, node-negative invasive breast carcinoma in the N·SAS-BC 01 trial;Breast Cancer;2022-04-18

5. Mitotic counts in one high power field in breast core biopsies is equivalent to counts in 10 high power fields;Pathology;2022-02